News
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Hims & Hers stock was trading lower but has since reversed and began trading higher after the company reported first-quarter ...
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Stocks fell on Tuesday as Wall Street reacted to the latest round of tariff uncertainty and some mixed earnings reports.These ...
But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
1d
24/7 Wall St. on MSNHims & Hers (HIMS) Blows Out Earnings ExpectationsHims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results